AssureCKD Accepted into ElevateIP Program to Strengthen Intellectual Property Surrounding for Kidney Screening and Diagnostic Technology
AssureCKD, a Canadian medical device company developing point-of-care solutions for chronic kidney disease (CKD) detection, is pleased to announce its acceptance into the ElevateIP Program, a federally supported initiative designed to help Canadian innovators protect, manage, and commercialize their intellectual property (IP).
Through this program, AssureCKD will receive funding to cover up to 80% of patent costs incurred after June 11, 2025. This support will be instrumental in securing a strong intellectual property position for the company’s MATLOC screening and diagnostic platform. Although AssureCKD does not currently hold IP directly, the University of Manitoba, its long-standing research collaborator, has agreed to assign relevant rights to the company at the earlier of 1) FDA Clearance and/or 2) A Series A financing, enabling access to ElevateIP’s funding and strategic support.
“This acceptance is a major step forward in strengthening our IP portfolio, which is critical to our long-term commercialization strategy,” said Harrison Ross, CEO of AssureCKD. “The ElevateIP team’s guidance and funding will help us protect our innovations, expand our competitive advantage, and position MATLOC for global market success.”
The ElevateIP Program, funded by the Government of Canada, connects companies with IP professionals and resources to help them leverage their innovations for growth. For AssureCKD, this partnership will ensure the company’s proprietary technology remains protected as it advances toward regulatory clearance and commercialization.
About AssureCKD
AssureCKD is developing MATLOC, a lab-equivalent diagnostic platform designed to screen, diagnose, and monitor chronic kidney disease at the point-of-care. By enabling rapid, accessible, and cost-effective testing in primary care and decentralized settings, AssureCKD aims to increase screening rates and facilitate earlier intervention, ultimately improving outcomes and reducing expensive healthcare costs.